This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy
by Debasmita Chatterjee
Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Top Research Reports for Apple, AMD & Applied Materials
by Mark Vickery
AAPL, AMD and AMAT lead today's top research picks, with insights on growth drivers, challenges, and shifting tech demand.
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
by Moumi Mondal
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why You Should Hold Cigna Stock in Your Portfolio for Now
by Zacks Equity Research
CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.
CVS or Cigna: Which Diversified Healthcare Stock Should You Own Now?
by Urmimala Biswas
CVS rallies on turnaround momentum and EPS growth, while CI is a defensive play with stable returns and a focused healthcare strategy.
The Zacks Analyst Blog Highlights Costco Wholesale, Chubb, Cigna, Global Self Storage and Natural Health Trends
by Zacks Equity Research
Costco eyes 11.3% EPS growth in 2025, Chubb boosts income outlook, and Cigna posts strong Q1 as Zacks spotlights five standout stocks.
Top Research Reports for Costco, Chubb & Cigna
by Mark Vickery
Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's solid Q1 performance amid margin pressures.
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
by Zacks Equity Research
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
by Urmimala Biswas
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
Markets Mostly Higher: Dow Kept Down by UNH Selling
by Mark Vickery
While UnitedHealthcare fights another unforeseen headwind, NVIDIA helped the Nasdaq cruise higher.
Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength
by Zacks Equity Research
CI increases adjusted earnings guidance for 2025 to $29.60 per share from the previous estimate of $29.50.
Cigna (CI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna (CI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 5.48% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
by Zacks Equity Research
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Curious about Cigna (CI) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Earnings Preview: Cigna (CI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.75% and 0.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
UnitedHealth (UNH) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
UnitedHealth (UNH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for March 20th
by Zacks Equity Research
AIN, EFX and CI have been added to the Zacks Rank #5 (Strong Sell) List on March 20, 2025.
Elevance Trades at a Bargain: Is it a Good Time to Buy ELV Stock?
by Kaibalya Pravo Dey
With a strengthening commercial business, ELV is seeing steady membership growth.
Humana (HUM) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Joint Gears Up for Q4 Earnings: Here's What to Expect
by Zacks Equity Research
JYNT's fourth-quarter results are likely to reflect higher Royalty fees, Software fees and Advertising fund revenues.
Molina (MOH) Up 13.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.